One of the trends I’ve been watching closely over the last few years is the growing number of platforms claiming that artificial intelligence can evaluate patent portfolios and determine which patents have commercial value. On the surface, that sounds efficient and even appealing, especially for companies holding large numbers of patents and trying to decide where to focus their time and resources. These tools analyze claims, citation history, technical classifications, and other data points, then generate scores that supposedly indicate which patents are worth pursuing.
The problem is that patent value is not determined by what is written in the patent. It is determined by what happens in the market. A patent describes an idea, but the market determines whether that idea can become a product, a process, a partnership, or a business. When companies rely too heavily on algorithmic scoring without looking at real-world commercial application, they often overlook some of their most valuable opportunities while spending time on assets that will never generate revenue.
What AI Can Evaluate — and What It Cannot
AI can be very useful for organizing large patent portfolios, identifying technical relationships, and highlighting patterns that would take a human analyst much longer to see. It can review claims, track citation networks, and categorize patents by technology field with impressive speed. For companies with thousands of patents, that kind of filtering can be helpful.
However, none of those data points answer the question that actually matters. They do not tell you whether a company in the real world would invest money to develop the technology, integrate it into a product, or license it for commercial use. A patent may look strong on paper and still have no viable path to market, while another patent that appears minor in a database may become extremely valuable once it is placed in the hands of the right industry partner.
Artificial intelligence cannot evaluate whether a technology solves a real operational problem, whether it can be manufactured economically, whether regulatory pathways exist, or whether a company has the capability to bring it to market. Those questions can only be answered through commercial engagement, not through document analysis.
Commercial Value Is Discovered Through the Market, Not the Patent File
The most reliable way to determine the value of intellectual property is to expose it to the market through a structured licensing or commercialization effort. When companies begin exploring licensing opportunities with operating businesses, something very different happens compared to internal evaluation. Industry partners look at the technology from a practical perspective, asking whether it fits into existing products, whether it improves performance, whether customers would adopt it, and whether it can be developed without excessive risk.
This type of real-world evaluation often reveals opportunities that no internal review would ever uncover. A patent that seems marginal inside a large portfolio may turn out to be exactly what a smaller company needs to launch a new product line, while a patent that looks impressive in a report may have no realistic commercial pathway at all. The market becomes the testing ground, and the companies that engage in licensing discussions learn far more about the value of their IP than any algorithm can tell them.
Why Large Patent Portfolios Often Contain Hidden Value
Large corporations frequently hold thousands, sometimes tens of thousands, of patents, yet only a small percentage of those assets are ever commercialized. This does not mean the rest have no value. In many cases, the company simply does not have the time, resources, or internal structure to explore every possible application. Large organizations tend to focus on core business units, leaving many technologies sitting dormant even though they could have value in other markets.
This creates a gap that licensing can fill. Large companies hold the intellectual property, but smaller companies often have the agility, focus, and entrepreneurial drive needed to develop it. When those two groups are connected through a structured licensing program, technologies that were previously ignored can become new products, new partnerships, and new revenue streams. That kind of value discovery does not happen through software scoring tools. It happens through deliberate market outreach.
The Biotech Industry Shows How This Model Works
One industry that has understood this for years is biotechnology. Large pharmaceutical companies routinely license early-stage technologies from universities, research labs, and small biotech firms, then fund development programs or form joint partnerships to bring those technologies to market. At the same time, large companies also license out technologies that do not fit their internal pipeline but may have value for someone else.
This model works because both sides understand their strengths. Smaller companies can move quickly, focus on specific innovations, and take development risks that large organizations may avoid. Larger companies provide resources, infrastructure, and global commercialization capability. Through licensing, each side does what it does best, and the technology has a better chance of reaching the market.
There is no reason this approach should be limited to pharmaceuticals. The same structure can apply to engineering, manufacturing, software, materials science, consumer products, and many other fields, but it requires a willingness to look beyond internal portfolio scoring and allow the market to participate in the evaluation.
Licensing Is Not Just Monetization — It Is a Discovery Process
Many companies think of licensing only as a way to generate royalties, but in practice licensing is also one of the most effective ways to discover where real value exists inside a portfolio. When patents are presented to industry partners, tested in real applications, and evaluated by companies that might actually use them, new opportunities often emerge that no internal analysis predicted.
Through a structured licensing program, technologies are exposed to people who understand the market, the manufacturing realities, and the customer needs. That process reveals which ideas have commercial potential and which ones do not. In that sense, licensing is not just a revenue strategy. It is a market-driven evaluation system that allows the strongest opportunities to surface naturally.
How We Evaluate Patent Portfolios at Licensing Consulting Group
When we work with companies that hold intellectual property, the focus is not on assigning theoretical scores to patents. The focus is on identifying realistic commercialization pathways and determining where the technology fits in the market. That means looking at the portfolio as a whole, understanding the industries where the IP could apply, and identifying companies that have the capability to develop it.
From there, a licensing strategy can be built that defines which assets should be offered, which markets to approach, and what type of deal structure makes sense. The process involves targeted outreach, real discussions with industry partners, and ongoing refinement as the market responds. This approach takes more effort than running a database analysis, but it produces results that are grounded in reality instead of theory.
Schedule a Short Consulting Call
If your company holds patents that may contain unrealized commercial value, or if you are unsure which assets in your portfolio are worth pursuing, it may be time to look at the IP from a market perspective instead of a document perspective. A short consulting call can help determine whether licensing, partnerships, or a structured commercialization program could unlock opportunities that internal analysis has missed.
You can schedule a short call here:
https://calendly.com/licensingcg/15-minute-video-meeting
Stay Informed on Licensing Strategy
If you want to continue learning how licensing programs uncover value that traditional portfolio reviews overlook, you can subscribe to the Licensing Consulting Group newsletter. The goal is to share real-world licensing examples, explain how deals are structured, and show how companies in different industries turn intellectual property into active revenue streams instead of letting it sit unused.
You can subscribe here:
https://licensingconsultinggroup.com/newsletter/
Patents do not become valuable because an algorithm says they are valuable. They become valuable when the right company finds a way to use them, and the only way that happens consistently is when the market is allowed to evaluate the technology.
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.